Financial benefit of combining two expensive drugs for CLL
The TAP CLARITY study: latest results and future plans
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MM